MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.280
-0.080
-1.83%
Closed 16:00 09/21 EDT
OPEN
4.350
PREV CLOSE
4.360
HIGH
4.533
LOW
4.280
VOLUME
100.99K
TURNOVER
--
52 WEEK HIGH
9.84
52 WEEK LOW
2.760
MARKET CAP
47.61M
P/E (TTM)
-0.2789
1D
5D
1M
3M
1Y
5Y
BRIEF-Acorda Therapeutics Inc Says Co Sent To BMR-Ardsley Park LLC Notice Of Exercise Of Its Early Termination Option
reuters.com · 18h ago
Acorda Therapeutics cutting staff by 15%, sees $20M in annual savings
Acorda Therapeutics (ACOR +2.5%) will cut its headcount by 15% to reduce costs and operating expenses, a move the company says will save $20M per year. Most of the cuts
Seekingalpha · 09/09 16:09
BRIEF-Acorda Announces 15% Reduction In Headcount, Management Changes
reuters.com · 09/09 12:22
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a corporate restructuring to reduce costs and more closely align operating expenses with expected revenue. The Company also announced changes to its management team.
Business Wire · 09/09 12:01
Acorda Therapeutics to Cut 15% of Staff; Names Chief Operating Officer, Chief Commercial Officer
MT Newswires · 09/09 10:43
Global Musculoskeletal Medicine Market SWOT Analysis,Key Indicators,Forecast 2027 : Mylan N.V., Dr. Reddy`s Laboratories Ltd.
Market Insight Reports · 08/30 12:10
Return on Capital Employed Insights for Acorda Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Acorda Therapeutics (NASDAQ:ACOR) posted sales of $31.79 million. Earnings were up 42.24%, but Acorda Therapeutics still reported an overall loss of $16.49 million.
Benzinga · 08/26 14:32
Canyon Capital Advisors Llc Buys Noble Corp, Valaris, Xilinx Inc, Sells Howmet Aerospace Inc, ...
GuruFocus News · 08/24 19:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACOR. Analyze the recent business situations of Acorda through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACOR stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 188
Institutional Holdings: 6.46M
% Owned: 58.09%
Shares Outstanding: 11.12M
TypeInstitutionsShares
Increased
7
350.76K
New
7
174.75K
Decreased
12
293.98K
Sold Out
7
143.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
John Kelley
Chief Executive Officer/President/Director
Ron Cohen
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller
Robert Morales
Chief Operating Officer
Lauren Sabella
Other
Burkhard Blank
Other
Kerry Clem
Independent Director
Peder Jensen
Independent Director
Sandra Panem
Independent Director
Lorin Randall
No Data
  • All
  • Financials
  • Insiders
More
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.